Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Diluted EPS of $1.81 per share (loss) for fiscal year 2025.
INOVIO PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.81 | +54.2% |
| 2024 | -$3.95 | +35.1% |
| 2023 | -$6.09 | +56.7% |
| 2022 | -$14.07 | +19.4% |
| 2021 | -$17.45 | -1530.8% |
| 2020 | -$1.07 | +11.6% |
| 2019 | -$1.21 | -15.2% |
| 2018 | -$1.05 | +3.7% |
| 2017 | -$1.09 | -7.9% |
| 2016 | -$1.01 | -129.5% |
| 2015 | -$0.44 | +31.2% |
| 2014 | -$0.64 | +55.2% |
| 2013 | -$1.43 | -146.6% |
| 2012 | -$0.58 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.87 | +2.2% | -42.6% |
| June 30, 2025 | -$0.61 | +48.7% | -19.6% |
| March 31, 2025 | -$0.51 | +61.1% | +42.7% |
| September 30, 2024 | -$0.89 | +41.4% | +25.2% |
| June 30, 2024 | -$1.19 | +26.1% | +9.2% |
| March 31, 2024 | -$1.31 | +30.7% | +13.8% |
| September 30, 2023 | -$1.52 | -913.3% | +5.6% |
| June 30, 2023 | -$1.61 | -250.0% | +14.8% |
- INOVIO PHARMACEUTICALS, INC. showed an increase of +54.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2025 period, INOVIO PHARMACEUTICALS, INC.’s diluted eps has declined by 212.1% (from $0.58 per share (loss) to $1.81 per share (loss)).
- The most recent figure is from INOVIO PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: